Research Article

Hyperbranched Cationic Glycogen Derivative-Mediated IκBα Gene Silencing Regulates the Uveoscleral Outflow Pathway in Rats

Rui Zeng,1 Jinmiao Li,1 Haijun Gong,1 Jiahao Luo,2 Zijing Li,1 Zhaoxing Ou,1 Si Zhang,1 Liqun Yang,2 and Yuqing Lan1

1Department of Ophthalmology, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
2Department of Polymer and Material Science, School of Chemistry, Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education, Guangdong Provincial Key Laboratory for High-Performance Polymer-Based Composites, Sun Yat-sen University, Guangzhou 510275, China

Correspondence should be addressed to Liqun Yang; yanglq@mail.sysu.edu.cn and Yuqing Lan; lyqglp@163.com

Received 13 June 2020; Revised 4 September 2020; Accepted 18 November 2020; Published 18 December 2020

Academic Editor: Rachida Bouhenni

Copyright © 2020 Rui Zeng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The role of the IκB/NF-κB signaling pathway in the uveoscleral outflow pathway was investigated with IκBα gene silencing mediated by the 3-(dimethylamino)-1-propylamine-conjugated glycogen (DMAPA-Glyp) derivative. The IκBα-siRNA-loaded DMAPA-Glyp complex was transfected into the ciliary muscles of rats by intracameral injection (labeled as the DMAPA-Glyp+siRNA group). The Lipofectamine™ 2000 (Lipo)/siRNA complex and the naked siRNA were set as the controls. The mRNA and protein expression of IκBα, NF-κBp65, and MMP-2 were analyzed by real-time PCR, western blotting, and in situ gelatin zymography. Nuclear translocation of NF-κBp65 was analyzed by immunofluorescence. Rat intraocular pressure (IOP) was monitored pre- and postinjection. Gene transfection efficiency and toxicity of the DMAPA-Glyp derivative were also evaluated. After RNA interference (RNAi), IκBα mRNA and protein expression were significantly inhibited. NF-κBp65 mRNA and protein expression showed no significant differences. Nevertheless, nuclear translocation of NF-κBp65 occurred in the DMAPA-Glyp+siRNA group. Both mRNA expression and activity of MMP-2 increased, with the largest increase in the DMAPA-Glyp+siRNA group. IOP in the DMAPA-Glyp+siRNA group fell to the lowest level on day 3 after RNAi. The levels of Cy3-siRNA in the ciliary muscle of the DMAPA-Glyp+siRNA group did not significantly decrease over time. At 7 and 14 d after RNAi, no significant pathological damage was detectable in the eyes injected with the DMAPA-Glyp derivative or the DMAPA-Glyp/siRNA complex. Taken together, our results suggest that downregulation of IκBα expression in the ciliary muscle plays a crucial role in reducing the IOP values of rats. IκBα may become a new molecular target for lowering IOP in glaucoma. The DMAPA-Glyp derivative is safe and feasible as an effective siRNA vector in rat eyes.

1. Introduction

Glaucoma is the second leading cause of blindness in the world according to the World Health Organization [1]. Pathological intraocular hypertension is the main risk factor leading to optic nerve damage in glaucoma. Lowering intraocular pressure (IOP) is currently the only method that has been strictly proven to be an effective approach to glaucoma treatment [2]. The IOP-lowering eye drops currently in clinical use must be administered at least once per day and require long-term use, which may damage the ocular surface and cause various ocular symptoms. Consequently, the compliance of patients often declines, leading to irreversible impairment of visual function. Therefore, it is essential to find a means of lowering IOP that offers a better pressure-lowering and more long-lasting effect with fewer side effects.

The vast majority of glaucoma cases result from the elevation of IOP due to an increasing aqueous humor outflow resistance. Uveoscleral drainage of the aqueous humor accounts for 10–20% of the total aqueous humor outflow and is a non-pressure-dependent pathway which is functional when the IOP is higher than 4 mmHg [3] and therefore...
plays a major role in the treatment of glaucoma. The ciliary muscle is the flow restriction site of this pathway. Remodeling of the ciliary muscle extracellular matrix (ECM) plays a nonnegligible role in the drainage of the aqueous humor via this pathway. An imbalance between matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of matrix metalloproteinases (TIMPs), is one of the major factors leading to the abnormal deposition of ECM in the aqueous humor outflow pathway [4]. Therefore, MMPs/TIMPs are critical regulators of IOP.

Previous works have reported that prostaglandins could degrade ciliary muscle ECM by promoting the synthesis of MMPs or by increasing MMP activity in the uveoscleral pathway, resulting in reducing aqueous humor outflow resistance, increasing aqueous humor outflow, and lowering IOP [5, 6]. However, the upstream molecular regulation mechanism of such effect is unclear at present. As an important transcription factor discovered recently, nuclear factor kappa B (NF-κB) is expressed in a variety of cells, which constitutes a system together with its inhibitor IκB that participates in various physiological and pathological processes as well as in the regulation of some MMPs [7, 8]. We had recently demonstrated in human ciliary muscle cells in vitro that the downregulation of IκBα expression by RNA interference (RNAi) could trigger the transcriptional activity of NF-κB, thereby increasing MMP-2 expression and downregulating TIMP-2 expression [9]. However, it still remains unclear whether the IκB/NF-κB system participates in the regulation of MMP-2 expression and activity, thereby affecting the uveoscleral outflow in vivo.

The RNAi technique has been used extensively in research on the molecular and biochemical mechanisms of intracellular signaling pathways. Small interfering RNA (siRNA), which is an important effector of RNAi, can be easily degraded by nucleases and is not readily transported across the cellular membrane due to its hydrophilicity and negative charge. Therefore, to prevent siRNA degradation and promote siRNA transfection efficiencies, it is necessary to select an appropriate delivery vector. Nanoparticle delivery vectors, currently the most effective nonviral vectors, have high transfection efficiencies and offer many advantages such as low immunogenicity, low toxicity, high stability, and ease of preparation [10], yielding great application prospects in gene therapy [11]. In a previous study, we successfully synthesized a hyperbranched cationic glycogen derivative, 3-(dimethylamino)-1-propylamine-conjugated glycogen (DMAPA-Glyp), and proved that DMAPA-Glyp, which exhibits good biocompatibility and low cytotoxicity, improves the stability of siRNA in serum and prolongs the interference effect of siRNA [12].

In the present study, IκBα-siRNA was transfected into rat ciliary muscle in vivo mediated by DMAPA-Glyp. The resulting changes in IκBα, NF-κBp65, and MMP-2 expression in the ciliary muscle and in the IOP of rats were observed. The objectives of the study were to further investigate the molecular mechanism of the IκB/NF-κB system in regulation of the uveoscleral outflow pathway and to evaluate the efficacy and safety of DMAPA-Glyp as a siRNA vector in rat eyes.

2. Materials and Methods

2.1. Materials. The DMAPA-Glyp derivative and the solution containing the DMAPA-Glyp/siRNA complex were prepared according to our previous work [12]. 100 mg of DMAPA-Glyp was dissolved in 10 ml of sterilized triple-distilled water and stored at room temperature overnight to formulate a DMAPA-Glyp stock solution at 10 mg/ml. The stock solution was stored at 4°C and diluted to a 1 mg/ml working solution in sterilized triple-distilled water before use. Based on the weight ratio of WDMAPA-Glyp/WsiRNA = 5, Cy3-labeled siRNA (1 μg) was added to 5 μl of solution containing 5 μg of DMAPA-Glyp. The mixture was incubated at room temperature for 10–15 min to yield the DMAPA-Glyp/siRNA complex.

The siRNA used in the experiments was designed and synthesized by Guangzhou RiboBio Co., Ltd. (Guangzhou, China). The sequences of the siRNA duplex targeting the rat IκBα gene (NM_001105720) were as follows: sense strand, 5′ CUACGAGUCUGUGUUUdTD3 ′; antisense strand, 5′ AACACACAGUCAUGGdTD3 ′. A nonspecific control siRNA duplex (NC-siRNA) and a Cy3- or Cy5-labeled NC-siRNA duplex, all 21 bp in length, were also prepared.

2.2. Animals. All animal procedures and methods were conducted in accordance with NIH guidelines for the care and use of laboratory animals and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The research protocol was approved by the Ethics Committee of Zhongshan Ophthalmic Center at Sun Yat-sen University in China.

Male Wistar rats, free of eye disease and weighing 200–250 g, were provided by the Experimental Animal Center of Sun Yat-sen University (Guangzhou, China). The rats were acclimatized in a specific pathogen-free (SPF) laboratory for 1 week before initiation of the study. Rats were anesthetized with an intraperitoneal injection of 10% chloral hydrate (300 mg/kg of body weight) and with topical 0.5% proxymetacaine hydrochloride drops (Alcaine, Alcon, Fort Worth, USA). At the end of the experiments, rats were euthanized by an overdose of 10% chloral hydrate. The animal experiment was conducted in the Experimental Animal Center of Zhongshan Ophthalmic Center.

2.3. Selection of Optimal Delivery Route. The rats were randomly divided into three groups: an intravitreal injection group, a ciliary muscle injection group, and an intracameral injection group. The DMAPA-Glyp/Cy3-siRNA complexes were transfected into rat eyes with these three delivery routes, respectively, and the optimal one was then selected. All injections were administered in the left eye of the rats.

2.3.1. Intravitreal Injection. The rats were anesthetized as described above. The superonasal sclera was exposed, and a microsyringe with a 33-gauge needle (Hamilton Bonaduz AG, Switzerland) was used to inject 10 μl of the DMAPA-Glyp/Cy3-siRNA complex (containing 1 μg of siRNA) 1.5 mm behind the corneal limbus into the vitreous cavity.
under a surgical microscope (Leica, Heerbrugg, Switzerland) [13]. Conventional feeding was used after injection.

2.3.2. Ciliary Muscle Injection. The rats were anesthetized as described above. We carried out the intraciliary muscle injection through a tunneled corneal incision. A microsyringe with a 33-gauge needle was inserted slightly deeper for a distance of 1 mm until it had crossed the corneal limbus. Then, 10 μl of the DMAPA-Glyp/Cy3-siRNA complex (containing 1 μg of siRNA) was injected under a surgical microscope [14]. Conventional feeding was performed after injection.

2.3.3. Intracameral Injection. The rats were anesthetized as described above. A microsyringe (33-gauge needle) was used to inject 10 μl of the DMAPA-Glyp/Cy3-siRNA complex (containing 1 μg of siRNA) through the peripheral cornea into the anterior chamber of rats under a surgical microscope. Care was taken to prevent damage to the lens and iris [15]. Conventional feeding was performed after injection.

2.3.4. Selection of Optimal Delivery Route. The optimal way for effective delivery of the transfection composite to the ciliary muscle was selected. 24 h after injection, rat eyes were removed under anesthesia and embedded in OCT (Sakura Finetek USA Inc., Torrance, USA). After quick freezing at -80°C, 7 μm frozen sections were prepared which were fixed in 4% paraformaldehyde and incubated with 4,6-diamidino-2-phenylindole (DAPI) nuclear staining solution (Beyotime Institute of Biotechnology, Shanghai, China). The distribution of DMAPA-Glyp/Cy3-siRNA complexes (red fluorescence) in rat ciliary muscle was observed under a fluorescence microscope (Carl Zeiss Meditec AG, Jena, Germany).

2.3.5. Immunofluorescence Staining of α-SMA. Frozen sections of rat eyes from the intracameral injection group were used for immunofluorescence staining of α-smooth muscle actin (α-SMA) to localize ciliary muscle. They were fixed in 4% paraformaldehyde for 10 min and blocked with normal goat serum at room temperature for 1 h. This was followed by incubation with anti-α-SMA mouse monoclonal antibody (1:100) (Sigma-Aldrich, St. Louis, USA) at 4°C overnight and subsequent incubation with fluorescein isothiocyanate (FITC-) labeled goat anti-mouse IgG (1:50) (Sigma-Aldrich, St. Louis, USA) at room temperature for 2 h. Finally, the sections were incubated with DAPI nuclear staining solution at room temperature for 5 min, mounted with an antifluorescent quenching agent (Beyotime Institute of Biotechnology, Shanghai, China) and observed under a fluorescence microscope.

2.4. Optimization of siRNA Transfection Dose

2.4.1. Fluorescence Microscopy. The rats were randomly divided into three groups: a 1 μg group, a 3 μg group, and a 5 μg group. Complexes containing various doses of Cy3-siRNA and DMAPA-Glyp were prepared as described above, and 10 μl of each complex was intracamerally injected into rat eyes. 24 h later, the eyes were removed under anesthesia to prepare frozen sections. The distribution of red fluorescence in the ciliary muscles of the rats in each group was observed under a fluorescence microscope.

2.4.2. Semiquantitative RT-PCR. The rats were randomly divided into five groups: a phosphate-buffered saline (PBS) group; an NC-siRNA group; and 1 μg, 3 μg, and 5 μg Lipo groups. DMAPA-Glyp were formulated into complexes as described above, and 10 μl of a complex was intracamerally injected into rat eyes. The PBS group was injected with an equal volume of sterilized PBS as the control. 24 h later, the eyeballs were removed under anesthesia, and the ciliary body was separated under a dissecting microscope (Carl Zeiss Meditec AG, Jena, Germany) and placed in a RNase-free glass homogenizer tube. 300 μl of RNAiso Plus (Takara Bio Inc., Kyoto, Japan) was added to the sample, and the sample was homogenized in an ice bath until no visible particles remained. The homogenate was transferred to an RNase-free 1.5 ml centrifuge tube, allowed to stand at room temperature for 5 min, and centrifuged at 12,000 rpm and 4°C for 5 min. The supernatant was removed to a new RNase-free centrifuge tube. Total RNA was extracted according to the protocol provided with the RNAiso Plus kit. The cDNA was synthesized by reverse transcription using the PrimeScript™ RT Reagent Kit (Takara Bio Inc., Kyoto, Japan) according to the manufacturer’s protocol. Semiquantitative RT-PCR was performed using a Premix Ex Taq™ Version 2.0 (loading dye mix) kit (Takara Bio Inc., Kyoto, Japan). The cycle parameters were as follows: 98°C for 10 sec, 60°C for 30 sec, and 72°C for 30 sec, with 24 cycles for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 30 cycles for Lipo. The primer sequences of GAPDH and Lipo are listed in Table 1. The PCR products were subjected to electrophoresis on 2% agarose gels and visualized under ultraviolet illumination using an INFINITY 3026 gel image machine (Vilber Lourmat Deutschland GmbH, Eberhardzell, Germany).

2.5. Evaluation of the siRNA Transfection Efficiency of the DMAPA-Glyp Derivative. The rats were randomly divided into three groups: the siRNA group, the Lipofectamine™ 2000 (Lipo) (Invitrogen, Carlsbad, USA) + siRNA group, and the DMAPA-Glyp+siRNA group. DMAPA-Glyp and Lipo were used separately to load 5 μg of Cy3-siRNA, and 10 μl of each complex was intracamerally injected into rat eyes, with naked siRNA as the control. At 24, 48, and 72 h after injection, the eyes were removed under anesthesia, and frozen sections were prepared. The distribution of red fluorescence in the ciliary muscle of rats in each group was observed under a fluorescence microscope.

2.6. The DMAPA-Glyp Derivative-Mediated Lipo-siRNA Transfection In Vivo. The experiment involved six groups of rats (Table 2). Each group was transfected by intracameral injection as described above with a volume of 10 μl per eye.

2.6.1. Lipo, NF-kBp65, and MMP-2 Gene Expression Assay after RNAi

(1) Real-Time PCR. The rats were anesthetized at 24, 48, and 72 h after intracameral injection. The eyes were removed, and
The relative expression of target gene mRNA was calculated by a Ct method [16]. The primer sequences of GAPDH, IκBα, and MMP-2 were listed in Table 1. The former were used for immunochemistry and embedded in OCT. After quick freezing at -80°C, 7 μm thick and 10 μm thick frozen sections were prepared. The former were used for immunofluorescence staining of NF-κBp65, as described above, at an anti-NF-κBp65 rabbit monoclonal antibody dilution of 1:50 (Cell Signaling Technology, Danvers, USA). The sections were observed under a fluorescence microscope. Assessment of the NF-κBp65 nuclear translocation was carried out by quantifying the intensity of green fluorescence in the nuclei of ciliary muscle area in three sections for each eye by using Image-Pro Plus software (Media Cybernetics, US).

2.6.2. NF-κBp65 Nuclear Translocation and MMP-2 Activity Assays after RNAi. At 24, 48, and 72 h after intracameral injection, the rat eyes were immediately removed under anesthesia and embedded in OCT. After quick freezing at -80°C, 7 μm thick and 10 μm thick frozen sections were prepared. The former were used for immunofluorescence staining of NF-κBp65, as described above, at an anti-NF-κBp65 rabbit monoclonal antibody dilution of 1:50 (Cell Signaling Technology, Danvers, USA). The sections were observed under a fluorescence microscope. Assessment of the NF-κBp65 nuclear translocation was carried out by quantifying the intensity of green fluorescence in the nuclei of ciliary muscle area in three sections for each eye by using Image-Pro Plus software (Media Cybernetics, US).

The 10 μm thick frozen sections were used for in situ gelatin zymography to analyze MMP-2 activity in rat ciliary muscle, which was assayed using an in situ gelatin zymography fluorescence staining kit for MMP-2 (GenMed Sciences Inc., Wilmington, USA) with the preparation kept away from light. The staining solution (Reagent B) was

Table 1: Nucleotide sequences of primers for PCR.

| Gene    | Primer sequence (5' ‐3') | Product size (bp) |
|---------|--------------------------|-------------------|
| IκBα    | Forward                  | TGACCATGGAACTGTATTGTGCAG | 95 |
|         | Reverse                  | GATCACAGGCACTGGAGTGA |  |
| NF-κBp65| Forward                  | CGAGCTATTTGCTGCTGCTTC | 139 |
|         | Reverse                  | TTGAGATCTGCCAGGTGGTA |  |
| MMP-2   | Forward                  | TGTGGCACCACCAGGAGATTA | 85 |
|         | Reverse                  | CTGAATTTACCACCAGTGAC |  |
| GAPDH   | Forward                  | GCCACAGTCAGGCTGAGAGT | 143 |
|         | Reverse                  | ATGGTTGGAAGACGCCAGTA |  |

Abbreviations: MMP-2—matrix metalloproteinase-2; GAPDH—glyceraldehyde 3-phosphate dehydrogenase.

Table 2: Grouping and treatment of animals.

| Group            | Treatment*                          |
|------------------|-------------------------------------|
| PBS group        | PBS                                 |
| DMAPA-Glyp group | DMAPA-Glyp solution containing 25 μg of DMAPA-Glyp |
| DMAPA-Glyp+NC group | DMAPA-Glyp and NC-siRNA complex containing 25 μg of DMAPA-Glyp and 5 μg of NC-siRNA |
| siRNA group      | IκBα-siRNA solution containing 5 μg of IκBα-siRNA |
| Lipo+siRNA group | Lipofectamine™ 2000 and IκBα-siRNA complex containing 1.5 μl of Lipofectamine™ 2000 and 5 μg of IκBα-siRNA |
| DMAPA-Glyp+siRNA group | DMAPA-Glyp and IκBα-siRNA complex containing 25 μg of DMAPA-Glyp and 5 μg of IκBα-siRNA |

*Intracameral injection with a volume of 10 μl per eye. Abbreviations: PBS—phosphate-buffered saline; DMAPA-Glyp—3-(dimethylamino)-1-propylamine-conjugated glycogen; NC-siRNA—nonspecific control siRNA; Lipo—Lipofectamine™ 2000.
thawed and preheated at room temperature, and the colloidal solution (Reagent A) was heated and thawed in a constant-temperature water bath at 60°C. Then, 80 μl of the colloidal solution was pipetted into a 1.5 ml centrifuge tube and incubated in a temperature-controlled water bath at 37°C for 10 min. Meanwhile, the staining solution was instantaneously preheated at 37°C, and 10 μl of the preheated staining solution was added to the colloidal solution. The mixture was immediately added to unfixed frozen sections, and the sections were incubated at 4°C for 10 min until the colloid had coagulated. The sections were then incubated at 37°C for 24 h and observed under a fluorescence microscope. The fluorescence level counting in the area of the ciliary muscle was performed to measure the MMP-2 activity by using Image-Pro Plus software.

2.6.3. Analysis of IOP Changes in Rats after RNAi. The rats were randomly divided into the following four groups: the PBS group, the DMAPA-Glyp group, the DMAPA-Glyp+NC group, and the DMAPA-Glyp+siRNA group. We measured rat IOP under topical anesthesia continuously for 3 d preinjection to determine the baseline value. And then, IOP was measured at 1–5 d, 1 w, and 2 w after intracameral injection by the same person at the same time of day (14:00) using a Tono-Pen XL Applanation Tonometer (Reichert, NY, USA). Each eye was measured three times, and the mean of the three measurements was taken as the IOP of the eye.

2.6.4. Evaluation of the Toxicity of the DMAPA-Glyp Derivative. At 7 d and 14 d after intracameral injection, anterior segment photography was conducted under a slit-lamp microscope (Carl Zeiss Meditec AG, Jena, Germany) to observe the occurrence of cataract, corneal edema, iris hyperemia, and hemorrhage among the rats in Section 2.6.3. Besides, the eyeballs of each group were removed at 7 d and 14 d after RNAi, and paraffin sections were stained with hematoxylin-eosin (HE). The rat eyes were fixed in 4% paraformaldehyde at 4°C for 24 h. After dehydration in a graded alcohol series and paraffin embedding, 4 μm sections were prepared. The sections were dewaxed with xylene followed by gradient hydration. All sections were stained with hematoxylin (Beyotime Institute of Biotechnology, Shanghai, China) for 5 min and rinsed with tap water. The sections were then differentiated with HCl-ethanol for 10 sec, immersed in tap water for 15 min, and placed in an eosin solution (Beyotime Institute of Biotechnology, Shanghai, China) for 1 min. Finally, the sections were conventionally dehydrated, cleared in xylene, and mounted in neutral balsam and then observed on a microscope (Leica, Heerbrugg, Switzerland).

2.7. Statistical Analysis. The data were analyzed using SPSS 13.0 (SPSS Inc., Chicago, USA). The experimental data that were normally distributed are expressed as the mean ± standard deviation (−χ ± s). Multiple comparisons of the means were conducted using one-way ANOVA. Pairwise comparison was performed using the LSD t-test. Comparisons of mean values between two groups were analyzed by Student’s t-test. All experiments were repeated at least three times under the same conditions, and the final results were averaged. The test of significance was conducted at the level α=0.05.

3. Results

3.1. Selection of Delivery Route. There was no remarkable distribution of red fluorescence in the ciliary body after intravitreal injection (Figure 1(a)); only a small amount of scattered fluorescence was visible in the ciliary muscle and ciliary processes after ciliary body injection (Figure 1(b)). A large amount of the DMAPA-Glyp/Cy3-siRNA complexes were found in the ciliary muscle after intracameral injection which was localized by α-SMA-positive immunofluorescence staining (green fluorescence). Some of them were observed in the trabecular meshwork as well. Meanwhile, the complexes were only rarely observed in the iris and corneal endothelium after intracameral injection (Figures 1(c)–1(f)).

3.2. Optimization of siRNA Transfection Dose. The group of rats that received 5 μg of IxBα-siRNA showed the strongest fluorescence distribution in the rat ciliary muscle and the greatest inhibitory effect on IxBα mRNA in the ciliary muscle at 24 h among rats transfected with various doses of siRNA (Figure 2).

3.3. Evaluation of the siRNA Transfection Efficiency of the DMAPA-Glyp Derivative. Fluorescence microscopic observation showed that the distribution of Cy3-siRNA in the ciliary muscle decreased over time in the Lipo+siRNA and siRNA groups. However, there was no remarkable decrease in Cy3-siRNA in the DMAPA-Glyp+siRNA group. A large amount of red fluorescence was distributed in the ciliary muscle of rats in that group at 72 h after transfection. Comparison of different groups at the same time points revealed higher fluorescence distribution in the ciliary muscle in the DMAPA-Glyp+siRNA group than in the other two groups (Figure 3).

3.4. Changes of IxBα Gene Expression after RNAi. IxBα mRNA expression was significantly decreased in the three IxBα siRNA-transfected groups (the siRNA group, the DMAPA-Glyp+siRNA group, and the Lipo+siRNA group) compared with the three control groups (the PBS group, the DMAPA-Glyp group, and the DMAPA-Glyp+NC group) at various time points after intracameral injection (24 h: F = 179.339, df = 35, P < 0.01; 48 h: F = 190.548, df = 35, P < 0.01; and 72 h: F = 85.191, df = 35, P < 0.01). The lowest IxBα mRNA expression occurred 24 h after transfection, and the inhibition rate gradually declined with time. There was a stronger inhibitory effect on mRNA in the DMAPA-Glyp+siRNA group than in the Lipo+siRNA and siRNA groups; the levels of IxBα mRNA in the DMAPA-Glyp+siRNA group showed 69.3%, 61.1%, and 49.9% inhibition compared with the three measurements at the same time points in the siRNA-transfected groups (the siRNA group, the DMAPA-Glyp+siRNA group, and the Lipo+siRNA group) at various time points after intracameral injection (24 h: F = 179.339, df = 35, P < 0.01; 48 h: F = 190.548, df = 35, P < 0.01; and 72 h: F = 85.191, df = 35, P < 0.01). The lowest IxBα mRNA expression occurred 24 h after transfection, and the inhibition rate gradually declined with time. There was a stronger inhibitory effect on mRNA in the DMAPA-Glyp+siRNA group than in the Lipo+siRNA and siRNA groups; the levels of IxBα mRNA in the DMAPA-Glyp+siRNA group showed 69.3%, 61.1%, and 49.9% inhibition at 24, 48, and 72 h, respectively, after transfection (Figure 4(a)).

At the level of protein expression, IxBα protein expression gradually decreased over time in the three IxBα siRNA-transfected groups. The decrease in IxBα protein expression was statistically significant in all three IxBα-siRNA-transfected groups at most time points, except that there was no significant difference in IxBα protein expression...
in the siRNA group compared with the three control groups at 24 h after transfection (24 h: $F = 10.674$, $df = 35$, $P < 0.01$; 48 h: $F = 85.078$, $df = 35$, $P < 0.01$; and 72 h: $F = 98.423$, $df = 35$, $P < 0.01$). The DMAPA-Glyp+siRNA group showed a more remarkable gene silencing effect than the Lipo+siRNA and siRNA groups, with inhibition of 23.3%, 51.0%, and 61.0% at 24, 48, and 72 h, respectively, after transfection (Figure 4(b)).

3.5. Changes in NF-κBp65 Gene Expression after RNAi. NF-κBp65 expression at the mRNA (24 h: $F = 1.846$, $df = 35$, $P > 0.05$; 48 h: $F = 1.483$, $df = 35$, $P > 0.05$; and 72 h: $F = 0.943$, $df = 35$, $P > 0.05$) and protein (24 h: $F = 1.565$, $df = 35$, $P > 0.05$; 48 h: $F = 1.192$, $df = 35$, $P > 0.05$; and 72 h: $F = 2.033$, $df = 35$, $P > 0.05$) levels showed no significant differences in the different groups at various time points after intracameral injection (Figure 5). Immunofluorescence staining of NF-κBp65 revealed increased nuclear expression of NF-κBp65 at 24, 48, and 72 h after transfection compared with the control group (24 h: $t = −19.427$, $df = 6$, $P < 0.01$; 48 h: $t = −21.784$, $df = 6$, $P < 0.01$; and 72 h: $t = −18.228$, $df = 6$, $P < 0.01$) (Figure 6).

Figure 1: The distribution of DMAPA-Glyp/Cy3-siRNA complexes in rat ciliary muscle after transfection via three different delivery routes ($\times 200$) ($n = 6$ per group). Notes. (a) Intravitreal injection group. (b) Ciliary muscle injection group—the white arrows indicate scattered fluorescence (red) in the ciliary muscle. (c–f) Intracameral injection group: (c) nuclei; (d) ciliary muscle fibers—α-SMA-positive immunofluorescence staining (green); (e) DMAPA-Glyp/Cy3-siRNA complexes (red); (f) merging of (c), (d), and (e)—the red arrow indicates DMAPA-Glyp/Cy3-siRNA complexes in the ciliary muscle. Abbreviations: cb—ciliary body; cm—ciliary muscle; ret—retina; scl—sclera; tm—trabecular meshwork; DMAPA-Glyp—3-(dimethylamino)-1-propylamine-conjugated glycogen; α-SMA—α-smooth muscle actin.
3.6. Changes in MMP-2 Gene Expression after RNAi. At 24 h after intracameral injection, MMP-2 mRNA expression significantly increased only in the DMAPA-Glyp+siRNA group compared with the three control groups ($F = 11.448$, $df = 35$, $P < 0.01$). At 48 h after transfection, MMP-2 mRNA expression significantly increased in the three IκBα-siRNA-transfected groups. The largest increase, an increase of approximately 3-fold compared with the PBS group, occurred in the DMAPA-Glyp+siRNA group ($F = 33.967$, $df = 35$, $P < 0.01$). At 72 h after transfection, except for the siRNA group, the increase in MMP-2 mRNA expression in the DMAPA-Glyp+siRNA and Lipo+siRNA groups was statistically significant compared with the three control groups ($F = 9.443$, $df = 35$, $P < 0.01$, Figure 7(a)).

Changes in MMP-2 activity in the rat ciliary muscle after intracameral injection were examined using in situ gelatin zymography of MMP-2 in the frozen sections. The results showed that MMP-2 activity changed insignificantly in the three IκBα-siRNA-transfected groups only at 24 h after transfection compared with the three control groups ($F = 1.691$, $df = 23$, $P > 0.05$). As the time of transfection was increased, the enzyme activity gradually increased (48 h: $F = 100.540$, $df = 23$, $P < 0.01$), reaching its highest level at 72 h (72 h: $F = 167.557$, $df = 23$, $P < 0.01$). Among the three IκBα-
siRNA-transfected groups, the DMAPA-Glyp+siRNA group showed the greatest elevation of MMP-2 activity. The MMP-2 activity increased to 2.5- and 3-fold at 48 and 72 h, respectively, compared with that in the PBS group (Figures 7(b) and 7(c)).

3.7. Changes in IOP in Rats after RNAi. The baseline of the rat IOP was 18.33 ± 1.21 mmHg and remained at a relatively stable level. After RNAi, the IOP of the rats in the DMAPA-Glyp+siRNA group decreased to 15.20 ± 1.47 mmHg at 3 d and to 16.75 ± 1.24 mmHg at 4 d. These differences were statistically significant compared with the IOPs of the rats in the three control groups (3 d: F = 21.508, df = 39, P < 0.01; 4 d: F = 8.934, df = 39, P < 0.01). The IOP in the DMAPA-Glyp+siRNA group receded to the baseline at 5 d (Figure 8).

3.8. Evaluation of the Toxicity of the DMAPA-Glyp Derivative. Anterior segment photography showed no occurrence of cataract, corneal edema, iris hyperemia, or hemorrhage in any of the groups at 7 and 14 d after intracameral injection (Figure 9(a)). HE staining revealed no significant inflammatory cell infiltration or pathological damage to the ciliary muscle or in the anterior chamber (Figure 9(b)).

4. Discussion

In this study, we prepared the DMAPA-Glyp/IRBα-siRNA complex using the DMAPA-Glyp derivative as the vector. Such complex was transfected into rat ciliary muscle to explore the role of the IκB/NF-κB signaling pathway in the uveoscleral outflow pathway.

IOP was the key part of our study. Therefore, the effect of different anesthetics on intraocular pressure should be a concern. A study showed that chloral hydrate sedation for outpatient pediatric ophthalmic procedures had no impact on IOP [17]. Inhalational agents, such as desflurane, isoflurane, and sevoflurane, could decrease IOP by suppressing the diencephalon (experimental studies have shown that the diencephalon has a direct effect on IOP [18]), reducing aqueous humor production, increasing aqueous humor outflow, and relaxing the extraocular muscles [19]. It was generally believed that propofol induction caused a decrease in systemic arterial pressure, which might cause a sharp drop in IOP [20]. Many studies suggested that ketamine elevated IOP in pediatric patients [21] and in healthy dogs [22, 23]. By comparing the above agents, we finally chose chloral hydrate to avoid the effect on the results of IOP.
In the course of our experiment, intravitreal injection, ciliary muscle injection, or intracameral injection into a rat eye took only about 5 seconds, so that topical anesthesia with 0.5% proxymetacaine hydrochloride drops combined with chloral hydrate sedation was enough. Furthermore, our experiment was supervised by Prof. Yuqing Lan, and no rats died throughout the course of the experiment.

The siRNA-loaded cationic polymer complexes could effectively improve the pharmacokinetics and targeting of siRNA in vivo [24, 25]. Glycogen, coming from animals, is a naturally hyperbranched polysaccharide with no toxicity, good biocompatibility, and good biodegradability [26–29]. We have reported the synthesis method of the DMAPA-Glyp derivative, and the stable DMAPA-Glyp/siRNA complex could be prepared at their weight ratio of 5 [12]. Accordingly, the DMAPA-Glyp/siRNA complex was prepared based on such weight ratio here.

Selecting an effective delivery route for the safe and efficient delivery of siRNA to the target site is a prerequisite for successful in vivo RNAi. In the present study, we found that a more intense red fluorescence of Cy3-siRNA in the ciliary muscle was found at 24 h after intracameral injection than that was found after intravitreal or ciliary muscle injection. Moreover, the red fluorescence was located at the sites that displayed green fluorescence indicating immunofluorescence staining for α-SMA (smooth muscle α-actin), a specific component of smooth muscle, whose antibody exhibits no cross-reaction with desmin, nor does it react with other proteins.

Figure 4: Examination of IκBα mRNA and protein levels at 24, 48, and 72 h after RNAi. The error bars represent the standard deviation calculated from three parallel experiments (n = 6 per group). Notes. (a) IκBα mRNA expression was quantified by real-time PCR. Expression levels were normalized with GAPDH, and the values were normalized with β-actin, which were represented in the bar graph. *P < 0.01 and **P < 0.05 compared with the PBS group, the DMAPA-Glyp group, and the DMAPA-Glyp+NC group. Abbreviations: PBS—phosphate-buffered saline; DMAPA-Glyp—3-(dimethylamino)-1-propylamine-conjugated glycogen; NC—nonspecific control; Lipo—Lipofectamine™ 2000.

In the course of our experiment, intravitreal injection, ciliary muscle injection, or intracameral injection into a rat eye took only about 5 seconds, so that topical anesthesia with 0.5% proxymetacaine hydrochloride drops combined with chloral hydrate sedation was enough. Furthermore, our experiment was supervised by Prof. Yuqing Lan, and no rats died throughout the course of the experiment.

The siRNA-loaded cationic polymer complexes could effectively improve the pharmacokinetics and targeting of siRNA in vivo [24, 25]. Glycogen, coming from animals, is a naturally hyperbranched polysaccharide with no toxicity, good biocompatibility, and good biodegradability [26–29]. We have reported the synthesis method of the DMAPA-Glyp derivative, and the stable DMAPA-Glyp/siRNA complex could be prepared at their weight ratio of 5 [12]. Accordingly, the DMAPA-Glyp/siRNA complex was prepared based on such weight ratio here.

Selecting an effective delivery route for the safe and efficient delivery of siRNA to the target site is a prerequisite for successful in vivo RNAi. In the present study, we found that a more intense red fluorescence of Cy3-siRNA in the ciliary muscle was found at 24 h after intracameral injection than that was found after intravitreal or ciliary muscle injection. Moreover, the red fluorescence was located at the sites that displayed green fluorescence indicating immunofluorescence staining for α-SMA (smooth muscle α-actin), a specific component of smooth muscle, whose antibody exhibits no cross-reaction with desmin, nor does it react with other proteins.

Figure 4: Examination of IκBα mRNA and protein levels at 24, 48, and 72 h after RNAi. The error bars represent the standard deviation calculated from three parallel experiments (n = 6 per group). Notes. (a) IκBα mRNA expression was quantified by real-time PCR. Expression levels were normalized with GAPDH, and the values were normalized with β-actin, which were represented in the bar graph. *P < 0.01 and **P < 0.05 compared with the PBS group, the DMAPA-Glyp group, and the DMAPA-Glyp+NC group. Abbreviations: PBS—phosphate-buffered saline; DMAPA-Glyp—3-(dimethylamino)-1-propylamine-conjugated glycogen; NC—nonspecific control; Lipo—Lipofectamine™ 2000.
mesenchymal cells, epithelial cells, or cytoskeletal components. This suggests that the siRNA was effectively delivered to the ciliary muscle via intracameral injection which was selected as the delivery route for the subsequent experiments.

The DMAPA-Glyp/Cy3-siRNA complex was intracameral injected into rat eyes to evaluate its transfection efficacy, using the classical cationic transfection reagent Lipofectamine™ 2000 loading Cy3-siRNA and naked Cy3-siRNA as the controls. We then observed the distribution of red fluorescence caused by Cy3-siRNA in the ciliary muscle of each group at 24, 48, and 72 h after transfection. Loading of the Cy3-siRNA onto DMAPA-Glyp resulted in a higher transfection efficiency with more red fluorescence in the ciliary muscle than the control groups. This may be related to the hyperbranched structure of DMAPA-Glyp which improves its gene transfection performance and the excellent protective effect of DMAPA-Glyp on siRNA [12]. In a study of the dynamics of aqueous humor and morphology in the uveoscleral pathway, Toris et al. [30] suggested that the difficulty of a given tracer in entering the uveoscleral pathway is closely related to its molecular weight. FITC-dextran with molecular weights between 4000 and 150,000 rarely enter uveal vessels; instead, they mainly enter the suprachoroidal space through the ciliary muscle gap. Thus, it appears likely that the high transfection efficiency of DMAPA-Glyp is related to the molecular weight and the particle size of the DMAPA-Glyp/siRNA complex.

To evaluate the performance of DMAPA-Glyp as a vector for in vivo transfection, we used the Lipofectamine/siRNA complex and naked siRNA as the controls and compared their
Figure 6: NF-κBp65 nuclear translocation at 24, 48, and 72 h after RNAi by immunofluorescence (×400) (n = 4 per group). Notes. (a) The white arrows indicate increased nuclear expression of NF-κBp65 in the DMAPA-Glyp+siRNA group; the asterisks indicate the weak nuclear signal of NF-κBp65 in the DMAPA-Glyp+NC group; the solid line rectangle indicates the magnifying region of the nuclear expression of NF-κBp65. (b) The fluorescence level counting of NF-κBp65 in the nuclei of the ciliary muscle was quantified to confirm NF-κBp65 nuclear translocation, and the values were represented in the bar graph. The error bars represent the standard deviation calculated from three parallel experiments. *P < 0.01, compared with the DMAPA-Glyp+NC group. Abbreviations: DAPI—4,6-diamidino-2-phenylindole; cb—ciliary body; cm—ciliary muscle; scl—sclera; DMAPA-Glyp—3-(dimethylamino)-1-propylamine-conjugated glycogen; NC—nonspecific control.
inhibitory effects on IxBα gene expression of the ciliary muscle after intracameral injection. The more remarkable gene silencing effect in the DMAPA-Glyp+siRNA group at the mRNA and protein levels indicates that the DMAPA-Glyp-/siRNA complex shows significantly higher efficacy of suppression on IxBα than the controls.

NF-κB denotes a class of Rel protein dimer transcription factors that can specifically bind to DNA. The p50 and p65 heterodimers of NF-κB have been intensively studied, as has their trimer with 1xBα [31]. In the resting state, the nuclear localization signal on p50 in the trimer is masked, and the trimer is retained in the cytoplasm and remains inactive. When cells are subjected to various extracellular stimuli, IxBα is rapidly degraded, and the nuclear localization signal of NF-κBp50 is exposed; the p50 and p65 heterodimers then enter the nucleus and specifically bind to gene-specific sequences, thereby playing a regulatory role in transcription.

We suppressed IxBα expression via RNAi in the rat ciliary muscle; we then observed the effects of this intervention on NF-κBp65 expression and nuclear translocation, as well as MMP-2 expression and activity. There were no significant changes in NF-κBp65 mRNA or protein expression at 24, 48, or 72 h after RNAi. However, immunofluorescence staining showed NF-κBp65 translocation into the nuclei after RNAi. This was consistent with our previous study in human ciliary muscle cells [9]. The anti-NF-κBp65 rabbit monoclonal antibody we used in this study could recognize endogenous levels of total NF-κBp65 protein (both the inactive form of the p65 subunit, bound to p50 and 1xBα in the cytoplasm, and the active monomeric form in the nucleus). Therefore, despite the nuclear translocation of NF-κBp65, its total protein expression might not change significantly.

From real-time PCR, we found that all three IxBα-siRNA-transfected groups showed significantly and maximally increased MMP-2 mRNA expression at 48 h after intracameral injection. The largest increase in MMP-2 mRNA expression occurred in the DMAPA-Glyp+siRNA group at all three time points. Substrate zymography is the method that is most commonly used to analyze the expression of MMPs. Here, we used in situ gelatin zymography to assay and localize MMP-2 activity in rat ciliary muscle. The results showed that the highest level of MMP-2 activity in the three IxBα-siRNA-transfected groups was present at 72 h. The most obvious increase in MMP-2 activity occurred in the DMAPA-Glyp+siRNA group. These results indicate that along with NF-κB activation and nuclear translocation, MMP-2 activity also increases in the rat ciliary muscle.

We measured the IOP of rats and determined whether the increase in MMP-2 activity in the rat ciliary muscle affects the IOP after RNAi. The handheld Tono-Pen tonometer is an electronic applanation tonometer [32]. The IOP value measured using the Tono-Pen is correlated with corneal thickness and ocular axial length [33], as well as the intensity and angle of the contact between the tonometer and the cornea. Because IOP fluctuates with circadian rhythm [34], we had the same experimenter measure the IOP of rats using the same positioning of the instrument at the same time of day for each measurement.

Whether the animal is anesthetized or not and the type of anesthetic used can affect the IOP. Jia et al. [35] reported that anesthetization decreases IOP and increases the difference in IOP between animals and that IOP measurement is more accurate when the animal is in an awake state. In the present study, the IOP of the rats was measured after topical anesthesia with 0.5% proparacaine hydrochloride drops. The baseline IOP measured in this way was 18.33 ± 1.21 mmHg. This is generally consistent with the mean normal IOPs in rats reported by Bakalash et al. [36, 37], i.e., 17.37 ± 2.19 mmHg and 19.41 ± 1.68 mmHg. However, Sawada and Neufeld [38], using a pneumotonometer, found the normal IOP of awake Wistar rats to be 11.6 ± 0.7 mmHg. Additionally, Wang et al. [39], using a Tono-Pen, found the normal IOP of awake Wistar rats to be 22.96 ± 0.18 mmHg. Our experimental results show varying differences from the IOP values reported in those studies. This may be related to the differences in the measuring instruments used, differences in the measurement time, the technique of the operator, and/or the compliance of the animals.

Husain et al. [40] found that Latanoprost increases the aqueous humor outflow in the uveoscleral pathway by activating MMPs in the ciliary body, thereby lowering the IOP of rats. In the present study, MMP-2 activity in the rat ciliary muscle significantly increased in the DMAPA-Glyp+siRNA group at 3 d after intracameral injection. And the IOP of the rats in this group decreased to the lowest level at the same time after RNAi. We conjecture that the IOP reduction after injection of the DMAPA-Glyp/siRNA complex may occur because activated MMP-2 following NF-κB nuclear translocation degrades the ECM of the ciliary muscle and thus promotes uveoscleral outflow of the aqueous humor. The consequent change of the ECM in the ciliary muscle will be investigated in further studies. The IOP in the DMAPA-Glyp+siRNA group receded to the baseline at 5 d. The ocular hypotensive effect appeared to be short-lived in normotensive eyes of rats. Huang et al. [41] indicated that 0.5% timolol could lower the IOP in rat eyes with normal ocular pressure which was observed to last 6 hours after treatment, whereas 0.5% timolol still showed significantly great hypotension effects in a laser-induced ocular hypertension model in rats 7 days after treatment. Liu et al. [42] reported that RhoA siRNA (siRhoA) was applied to normal and DEX-induced elevated IOP mice by intracameral injection. In normal mice, injections of siRhoA induced decreases in IOP by 2 d, with recovery to baseline by 3 d, postinjection. For DEX-treated animals, IOP significantly decreased from 2 d to 5 d postinjection. The differences in IOP changes between the normal and hypertension model might be due to the different functional states of the aqueous humor outflow pathway. The hypotensive effect of DMAPA-Glyp/IxBα-siRNA in the ocular hypertension rat model needs to be investigated in the future.

However, several studies indicated the opposite conclusion in that NF-κB activity was a driver for increased outflow resistance in the TM. Hernandez et al. [43] showed that NF-κB was necessary for TGFβ2-induced ECM production and ocular hypertension. Wang et al. [44] showed that IL-1 produced endogenously by glaucomatous TM cells inhibited the apoptotic response to oxidative stress through NF-κB and increased outflow facility perhaps through its
Figure 7: Continued.
ability to stimulate expression of MMPs. These studies focused on the conventional outflow pathway, and the changes in ciliary muscle cells governing the unconventional route need to be further explored.

A large amount of the DMAPA-Glyp/Cy3-siRNA complexes were found in the ciliary muscle after intracameral injection. Meanwhile, some of them were observed in the trabecular meshwork as well (Figures 1–3). In a review concerning unconventional aqueous humor outflow, Johnson et al. [45] mentioned in the direct measurement of its flow rate that outflow of the tracer introduced into the anterior chamber through the conventional pathway is relatively fast (a minute or less) and fairly insensitive to tracer molecular size. In contrast, tracers draining through the unconventional pathway are retarded or captured as they move through the unconventional outflow pathway such that their transit may take up to two hours depending on tracer size, animal species, and dimensions of the eye. Thus, we have reason to infer that the longer time for which the DMAPA-Glyp/Cy3-siRNA complexes stay in the unconventional outflow pathway provides the complexes more opportunities to transfect into the ciliary muscle. Additionally, the appropriate molecular weight and particle size of the DMAPA-Glyp/siRNA complex, as mentioned above, induce the high transfection efficiency in the ciliary muscle. Therefore, we consider that the unconventional outflow pathway is the major contributor to the effect on IOP in response to IκBα gene silencing. As for the role of the DMAPA-Glyp/IκBα-siRNA complexes in the conventional outflow pathway, further studies will be conducted.

In addition to efficacy, a desired vector must meet the requirement of safety. In our previous study [12], the DMAPA-Glyp and DMAPA-Glyp/siRNA complex showed significantly lower cytotoxicity against human retinal

**Figure 7:** MMP-2 mRNA expression and activity at 24, 48, and 72 h after RNAi. Notes. (a) MMP-2 mRNA expression was quantified by real-time PCR. Expression levels were normalized with GAPDH. The error bars represent the standard deviation calculated from three parallel experiments (n = 6 per group). (b) The activity of MMP-2 was analyzed by in situ gelatin zymography. The stronger the green fluorescence in the ciliary muscle, the higher the MMP-2 activity (×200). The yellow solid line indicates the area of the ciliary muscle scanned for MMP-2 activity, and the values were represented in the bar graph. The error bars represent the standard deviation calculated from three parallel experiments (n = 4 per group). *P < 0.01 and **P < 0.05, compared with the PBS group, the DMAPA-Glyp group, and the DMAPA-Glyp+NC group. Abbreviations: PBS—phosphate-buffered saline; DMAPA-Glyp—3-(dimethylamino)-1-propylamine-conjugated glycogen; NC—nonspecific control; Lipo—Lipofectamine™ 2000; cb—ciliary body; cm—ciliary muscle; scl—sclera.

**Figure 8:** Changes in IOP in rats at 24, 48, and 72 h after RNAi. The error bars represent the standard deviation calculated from three parallel experiments (n = 10 per group). Notes. *P < 0.01, compared with the PBS group, the DMAPA-Glyp group, and the DMAPA-Glyp+NC group. Abbreviations: PBS—phosphate-buffered saline; DMAPA-Glyp—3-(dimethylamino)-1-propylamine-conjugated glycogen; NC—nonspecific control.
pigment epithelial (hRPE) cells when compared to branched polyethylenimine (bPEI). In this study, no pathological damage to the ciliary muscle or the anterior chamber was found in rats injected with DMAPA-Glyp alone or with the DMAPA-Glyp/siRNA complex. No rats died after injection with those above throughout the course of the experiment. These results prove that DMAPA-Glyp has excellent biocompatibility and no toxicity in rats.

5. Conclusions

Downregulation of IκBα expression in the ciliary muscle plays a crucial role in reducing the IOP values of rats. IκBα may become a new molecular target for lowering IOP in glaucoma. The DMAPA-Glyp derivative is safe and feasible as an effective siRNA vector in rat eyes.

Data Availability

The data used to support the findings of this study are included within this article.

Disclosure

The abstract of this manuscript had been presented as a poster in the ARVO Annual Meeting Abstract in Investigative Ophthalmology & Visual Science, volume 60, issue 9, July 2019.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Authors’ Contributions

Rui Zeng and Jinmiao Li contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (grant number 81570845). The authors would like to express their sincere gratitude to Dr. Phei Er Saw, Ph.D. for providing additional assistance with the critical revision of the article.
References

[1] M. L. Occhiutto, R. C. Maranhao, V. P. Costa, and A. G. Konstas, "Nanotechnology for medical and surgical glaucoma therapy—a review," *Advances in Therapy*, vol. 37, no. 1, pp. 155–199, 2020.

[2] J. Wierzbowska, J. Robaszkiewicz, M. Figurska, and A. Stankiewicz, "Future possibilities in glaucoma therapy," *Medical Science Monitor*, vol. 16, no. 11, pp. A252–A259, 2010.

[3] A. Bill, "The effect of ocular hypertension caused by red cells on the rate of formation of aqueous humor," *Investigative Ophthalmology*, vol. 7, no. 2, pp. 162–168, 1968.

[4] A. D. Nga, S. L. Yap, A. Samsudin, P. S. Abdul-Rahman, O. H. Hashim, and Z. Mimiwati, "Matrix metalloproteinases and tissue inhibitors of metalloproteinases in the aqueous humour of patients with primary angle closure glaucoma—a quantitative study," *BMC Ophthalmology*, vol. 14, no. 1, 2014.

[5] Y. H. Ooi, D. J. Oh, and D. J. Rhee, "Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells," *Investigative Ophthalmology & Visual Science*, vol. 50, no. 11, pp. 5259–5265, 2009.

[6] C. B. Toris, B. A. T. Gabelt, and P. L. Kaufman, "Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction," *SURVEY OF OPHTHALMOLOGY*, vol. 53, no. 6, pp. S107–S120, 2008.

[7] A. Piotrowska, I. Izykowska, M. Podhorska-Okolow, M. Zabel, and P. Dziedzic, "The structure of NF-κB family proteins and their role in apoptosis," *Postepy Hig Med Dosw*, vol. 62, pp. 64–74, 2008.

[8] K. Umezawa and Y. Lin, "Inhibition of matrix metalloproteinase expression and cellular invasion by NF-κB inhibitors of microbial origin," *Biochim Biophys Acta Proteins Proteom*, vol. 1868, no. 6, p. 140412, 2020.

[9] Y. Q. Lan, C. Zhang, J. H. Xiao et al., "Suppression of IkBα increases the expression of matrix metalloproteinase-2 in human ciliary muscle cells," *Molecular Vision*, vol. 15, pp. 1977–1987, 2009.

[10] P. Kesharwani, V. Gajbhiye, and N. K. Jain, "A review of nanocarriers for the delivery of small interfering RNA," *Biomaterials*, vol. 33, no. 29, pp. 7138–7150, 2012.

[11] S. L. Hart, "Multifunctional nanocomplexes for gene transfer and gene therapy," *Cell Biology and Toxicology*, vol. 26, no. 1, pp. 69–81, 2010.

[12] Z. Liu, H. Gong, R. Zeng et al., "Efficient delivery of NF-κB siRNA to human retinal pigment epithelial cells with hyperbranched cationic polysaccharide derivative-based nanoparticles," *International Journal of Nanomedicine*, vol. 10, pp. 2735–2749, 2015.

[13] K. Chiu, R. C.-C. Chang, and K.-F. So, "Intravitreal injection for establishing ocular diseases model," *Journal of Visualized Experiments*, no. 8, 2007.

[14] C. Bloquel, R. A. Bejiani, P. Bigey et al., "Plasmid electrotansfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-a soluble receptor in uveitis," *FASEB Journal*, vol. 20, no. 2, pp. 389–391, 2005.

[15] C. Kee, S. Sohn, and J. M. Hwang, "Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo," *Investigative Ophthalmology & Visual Science*, vol. 42, no. 12, pp. 2856–2860, 2001.

[16] K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method," *Methods*, vol. 25, no. 4, pp. 402–408, 2001.

[17] V. Varadaraj, B. Munoz, M. Karauoi et al., "Effect of chloral hydrate sedation on intraocular pressure in a pediatric population," *American Journal of Ophthalmology*, vol. 194, pp. 126–133, 2018.

[18] B. C. Samuels, N. M. Hammes, P. L. Johnson, A. Shekhar, S. J. McKinnon, and R. R. Allingham, "Dorsomedial/periforinal hypothalamic stimulation increases intraocular pressure, intracranial pressure, and the translaminar pressure gradient," *Investigative Ophthalmology & Visual Science*, vol. 53, no. 11, pp. 7328–7335, 2012.

[19] M. Mikhail, K. Sabri, and A. V. Levin, "Effect of anesthesia on intraocular pressure measurement in children," *Survey of Ophthalmology*, vol. 62, no. 5, pp. 648–658, 2017.

[20] K. Barclay, T. Wall, K. Wareham, and T. Asai, "Intraocular pressure changes in patients with glaucoma. Comparison between the laryngeal mask airway and tracheal tube," *Anaesthesia*, vol. 49, no. 2, pp. 159–162, 1994.

[21] K. Yoshikawa and Y. Murai, "The effect of ketamine on intraocular pressure in children," *Anesthesia and Analgesia*, vol. 50, no. 2, pp. 199–202, 1971.

[22] M. D. Smith, M. Barletta, K. A. Diehl, E. H. Hofmeister, and S. P. Franklin, "Effect of propofol and ketamine-diazepam on intraocular pressure in healthy premedicated dogs," *Veterinary Anaesthesia and Analgesia*, vol. 46, no. 1, pp. 36–42, 2019.

[23] E. H. Hofmeister, C. B. Mosunic, B. T. Torres, A. G. Ralph, P. A. Moore, and M. R. Read, "Effects of ketamine, diazepam, and their combination on intraocular pressures in clinically normal dogs," *American Journal of Veterinary Research*, vol. 67, no. 7, pp. 1136–1139, 2006.

[24] M. A. Behlke, "Progress towards in vivo use of siRNAs," *Molecular Therapy*, vol. 13, no. 4, pp. 644–670, 2006.

[25] S. Mocellin and M. Provenzano, "RNA interference: learning gene knock-down from cell physiology," *Journal of Translational Medicine*, vol. 2, no. 1, p. 39, 2004.

[26] J. L. Putaux, G. Potocki-Veronese, M. Remaud-Simeon, and A. Buleon, "α-D-Glucan-based dendritic nanoparticles prepared by in vitro enzymatic chain extension of glycogen," *Bio-macromolecules*, vol. 7, no. 6, pp. 1720–1728, 2006.

[27] A. Rolland-Sabate, M. G. Mendez-Montalvo, P. Colonna, and V. Planchnot, "Online determination of structural properties and observation of deviations from power law behavior," *Bio-macromolecules*, vol. 9, no. 7, pp. 1719–1730, 2008.

[28] A. Rolland-Sabate, P. Colonna, M. G. Mendez-Montalvo, and V. Planchnot, "Branching features of amyllopectins and glyco- gen determined by asymmetrical flow field flow fractionation coupled with multiangle laser light scattering," *Biomacromolecules*, vol. 8, no. 8, pp. 2520–2532, 2007.

[29] J. A. de Miranda, N. Cacita, and L. T. Okano, "Evaluation of amylopectin clusters and their interaction with nonionic surfactants," *Colloids and Surfaces. B, Biointerfaces*, vol. 60, no. 1, pp. 19–27, 2007.

[30] C. B. Toris, D. S. Gregerson, and J. E. Pederson, "Uveoscleral outflow using different-sized fluorescent tracers in normal and inflamed eyes," *Experimental Eye Research*, vol. 45, no. 4, pp. 525–532, 1987.

[31] D. L. Fleenor, J. H. Pang, and A. F. Clark, "Involvement of AP-1 in interleukin-1α-stimulated MMP-3 expression in human
trabecular meshwork cells,” *Investigative Ophthalmology & Visual Science*, vol. 44, no. 8, pp. 3494–3501, 2003.

[32] M. E. Pease, J. C. Hammond, and H. A. Quigley, “Manometric calibration and comparison of TonoLab and TonoPen tonometers in rats with experimental glaucoma and in normal mice,” *Journal of Glaucoma*, vol. 15, no. 6, pp. 512–519, 2006.

[33] B. E. Cohan and D. F. Bohr, “Measurement of intraocular pressure in awake mice,” *Investigative Ophthalmology & Visual Science*, vol. 42, no. 11, pp. 2560–2562, 2001.

[34] C. A. Rasmussen and P. L. Kaufman, “Primate glaucoma models,” *Journal of Glaucoma*, vol. 14, no. 4, pp. 311–314, 2005.

[35] L. Jia, W. O. Cepurna, E. C. Johnson, and J. C. Morrison, “Effect of general anesthetics on IOP in rats with experimental aqueous outflow obstruction,” *Investigative Ophthalmology & Visual Science*, vol. 41, no. 11, pp. 3415–3419, 2000.

[36] S. Bakalash, A. Kessler, T. Mizrahi, R. Nussenblatt, and M. Schwartz, “Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma,” *Investigative Ophthalmology & Visual Science*, vol. 44, no. 8, pp. 3374–3381, 2003.

[37] H. Schori, J. Kipnis, E. Yoles et al., “Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 6, pp. 3398–3403, 2001.

[38] A. Sawada and A. H. Neufeld, “Confirmation of the rat model of chronic, moderately elevated intraocular pressure,” *Experimental Eye Research*, vol. 69, no. 5, pp. 525–531, 1999.

[39] X. Wang, S. S.-W. Tay, and Y.-K. Ng, “An immunohistochemical study of neuronal and glial cell reactions in retinas of rats with experimental glaucoma,” *Experimental Brain Research*, vol. 132, no. 4, pp. 476–484, 2000.

[40] S. Husain, P. W. Yates, and C. E. Crosson, “Latanoprost-induced changes in rat intraocular pressure: direct or indirect?,” *Journal of Ocular Pharmacology and Therapeutics*, vol. 24, no. 4, pp. 367–372, 2008.

[41] P. Huang, Y. Xu, R. Wei et al., “Efficacy of tetrandrine on lowering intraocular pressure in animal model with ocular hypertension,” *Journal of Glaucoma*, vol. 20, no. 3, pp. 183–188, 2011.

[42] Q. Liu, K. Wu, X. Qiu, Y. Yang, X. Lin, and M. Yu, “siRNA silencing of gene expression in trabecular meshwork: RhoA siRNA reduces IOP in mice,” *Current Molecular Medicine*, vol. 12, no. 8, pp. 1015–1027, 2012.

[43] H. Hernandez, A. L. Roberts, and C. M. McDowell, “Nuclear factor-kappa beta signaling is required for transforming growth factor beta-2 induced ocular hypertension,” *Experimental Eye Research*, vol. 191, p. 107920, 2020.

[44] N. Wang, S. K. Chintala, M. E. Fini, and J. S. Schuman, “Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype,” *Nature Medicine*, vol. 7, no. 3, pp. 304–309, 2001.

[45] M. Johnson, J. W. McLaren, and D. R. Overby, “Unconventional aqueous humor outflow: a review,” *Experimental Eye Research*, vol. 158, pp. 94–111, 2017.